Loyal
Clinical-stage animal health company developing dog longevity drugs.
Cumulative raised across 2 rounds, totaling $145M.
Fundraising history.
Series B — $45M
Mar 2024Series B led by Bain Capital Ventures; existing investors participated.
Led by Bain Capital Ventures · with Valor Equity Partners, Khosla Ventures, First Round Capital, Box Group +2
Source ↗Series C — $100M
Feb 2026Series C led by age1 with participation from Baillie Gifford.
Led by age1 · with Baillie Gifford
Source ↗
Clinical-stage animal health company developing dog longevity drugs.
Loyal is a clinical-stage animal health company developing drugs intended to help dogs live longer, healthier lives. Its work focuses on FDA-regulated veterinary medicine and aging biology.
Press
Supports Loyal’s description, leadership, and announcements.
loyal.comLoyal | HomeSupports clinical-stage company description and current STAY study enrollment.
loyal.comLoyal | Clinical trialsSupports the STAY study details, 1,300 dogs, and 70 clinics.
loyal.comLoyal’s Series C: $100M to advance the first longevity drugSupports the February 11, 2026 Series C and total funding context.
loyal.comNot just for big dogs! Our senior dog program receives preliminary FDA efficacy acceptance (RXE)Supports FDA efficacy acceptance and total investment since founding.
loyal.comLoyal | For dog ownersSupports expanded conditional approval pathway and safety package acceptance.
businesswire.comLoyal Announces $45 Million Series B Financing to Continue Development of First FDA-Approved Dog Lifespan Extension Drug for Veterinary UseSupports the March 2024 Series B financing and investors.
linkedin.comCeline Halioua - Loyal | LinkedInSupports Celine Halioua identity, location, and education.